Anzeige
Mehr »
Login
Dienstag, 19.03.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Nach Milliarden-Deal - Übernahme-Karussell nimmt Fahrt auf!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1H65A | ISIN: NL0010391025 | Ticker-Symbol: PHGN
Tradegate
18.03.24
21:14 Uhr
1,033 Euro
+0,003
+0,29 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHARMING GROUP NV Chart 1 Jahr
5-Tage-Chart
PHARMING GROUP NV 5-Tage-Chart
RealtimeGeldBriefZeit
1,0281,04608:51
1,0361,04408:36

Aktuelle News zur PHARMING Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrPharming reports Q4 results2
FrEarnings call: Pharming Group N.V. sees steady growth with RUCONEST and Joenja5
DoPharming Group slips on 2023 net loss, 'weak' guidance7
DoPharming Group N.V. - 6-K, Report of foreign issuer1
DoPharming Group Q4 Loss Narrows - Update1
DoPharming Group NV reports results for the quarter ended in December - Earnings Summary2
DoPharming Group N.V.: Pharming Group reports fourth quarter and full year 2023 financial results52Full year 2023 total revenues increased by 19% to US$245.3 millionRecord fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to US$227.1...
► Artikel lesen
29.02.Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2023 financial results on March 14220Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year...
► Artikel lesen
08.02.Pharming Group N.V.: Pharming Group to participate in February investor conferences339Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences...
► Artikel lesen
08.01.What's Going On With Netherlands-Based Biopharma Company Pharming Shares Today?7
08.01.Pharming Group N.V. - 6-K, Report of foreign issuer2
08.01.Pharming Group issues full-year 2023 guidance2
08.01.Pharming Group jumps after it hikes Ruconest revenues guidance4
08.01.Pharming Group Projects 2023 Total Revenues To Rise 19%3
08.01.Pharming Group N.V.: Pharming Group announces updated full year 2023 guidance and Joenja U.S. launch update217Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end Leiden,...
► Artikel lesen
15.12.23Pharming Group N.V. - 6-K, Report of foreign issuer4
13.12.23Pharming To Develop Leniolisib For Additional PIDs Beyond APDS; Phase 2 Trial To Initiate In Q23
13.12.23Pharming Group N.V.: Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)154Initial development in PIDs with immune dysregulation linked to PI3K? signaling Phase 2 clinical trial initiation planned for 2Q 2024 Leiden, The Netherlands, December 13, 2023: Pharming...
► Artikel lesen
21.11.23Pharming Group N.V.: Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib210The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands...
► Artikel lesen
13.11.23Pharming Group N.V. - 6-K, Report of foreign issuer2
Seite:  Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1